Search Results

Your search for Weijing Sun, MD, FACP,Weijing Sun, MD, FACP matches 2 pages

Showing 1 - 2

By Weijing Sun, MD, FACP / June 10, 2015

Another Angiogenesis Inhibitor Shows Benefit in Metastatic Colorectal Cancer, but Where Do We Go Next?

The phase III RAISE trial—reported by Tabernero and colleagues in The Lancet Oncology1 and reviewed in this issue of The ASCO Post—demonstrated that ramucirumab (Cyramza), a fully human IgG1 monoclonal antibody to the vascular endothelial growth factor receptor 2 (VEGFR2) extracellular domain, in...

colorectal cancer

By Matthew Stenger / June 10, 2015

Addition of Ramucirumab to Second-Line FOLFIRI Improves Overall Survival in Metastatic Colorectal Cancer

In the phase III RAISE trial reported in The Lancet Oncology, Josep Tabernero, MD, PhD, Head of Medical Oncology at Vall d’Hebron Institute of Oncology, Barcelona, and colleagues found that the addition of the antiangiogenic anti–vascular endothelial growth factor receptor 2 (VEGFR2) antibody...

Nov

Today In Oncology

Search Results

Your search for Weijing Sun, MD, FACP,Weijing Sun, MD, FACP matches 2 pages

Another Angiogenesis Inhibitor Shows Benefit in Metastatic Colorectal Cancer, but Where Do We Go Next?

Addition of Ramucirumab to Second-Line FOLFIRI Improves Overall Survival in Metastatic Colorectal Cancer

What Is the Impact of a Colon or Colorectal Cancer Diagnosis on Younger Adults?

International Cancer Organizations Present Collaborative Work During Oncology Event in China

Is There a Role for Neoadjuvant Chemotherapy in HR-Positive, HER2-Negative Early Breast Cancer?

Suicide-Related Mortality in Male AYA Cancer Survivors

Four-Year Asian Subpopulation Data From the CheckMate 816 Trial of Neoadjuvant Nivolumab Plus Chemotherapy in Resectable NSCLC